Heart failure & cardiomyopathies
Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial
Authors' conclusion
Vericiguat use in the VICTORIA trial met criteria for intermediate value, but the incremental cost-effectiveness ratio estimates were sensitive to whether the analysis accounted for observed NT-proBNP treatment effect heterogeneity.
Study context
- Population
- Patients with high-risk HFrEF in the VICTORIA trial
- Participants
- 5,050 patients
- Comparison
- Vericiguat vs placebo
- Primary endpoint
- Incremental cost-effectiveness ratio, vericiguat vs placebo
- Follow-up
- Lifetime horizon
Methodological detailsUS health care sector perspective, lifetime horizon
- US health care sector perspective
- Lifetime horizon
Primary result
As reported in the abstract
Incremental cost-effectiveness ratio
$66 509 per QALY
allowing for treatment heterogeneity (NT-proBNP interaction)
Incremental cost-effectiveness ratio
$124 512 per QALY
without heterogeneity
Secondary outcomes
Quality-adjusted life expectancy, with interaction term
incremental discounted QALY 0.43
Quality-adjusted life expectancy, without interaction term
incremental discounted QALY 0.17
| Outcome | Incremental discounted costs |
|---|---|
| Incremental discounted costs (vericiguat minus placebo)With treatment interaction | $28 546 |
| Incremental discounted costs (vericiguat minus placebo)Without treatment interaction | $20 948 |
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →